Pipeline

Rivoceranib (Apatinib) is a small molecule drug candidate which has been approved in China and has completed Phase 1/2A development in the US. LSKB reached primary completion date for the global Phase 3 trial in GC 3rd line in February of 2019. LSKB projects regulatory approvals in 2020 if approved by the Food and Drug Administration. It is being developed for the treatment of certain solid tumor cancers including gastric cancer, colorectal cancer, adenoid cystic carcinoma, and hepatocellular carcinoma.

Learn More About Rivoceranib